Compare KOSS & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOSS | IPSC |
|---|---|---|
| Founded | 1953 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6M | 47.6M |
| IPO Year | N/A | 2021 |
| Metric | KOSS | IPSC |
|---|---|---|
| Price | $4.85 | $0.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 25.6K | ★ 1.0M |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $13,493,080.00 | ★ $113,337,000.00 |
| Revenue This Year | N/A | $1,589.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 11.58 | ★ 4122.69 |
| 52 Week Low | $4.00 | $0.34 |
| 52 Week High | $8.59 | $1.74 |
| Indicator | KOSS | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 51.05 | 48.16 |
| Support Level | $4.81 | $0.50 |
| Resistance Level | $4.99 | $0.56 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 71.43 | 72.54 |
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.